Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

720 ARTÍCULOS , VIENDO DEL 271 AL 285

Unveiling the role of astrogliosis in Alzheimer's disease Pathology: Insights into mechanisms and therapeutic approaches

Paidlewar M, Kumari S, Dhapola R, Sharma P, HariKrishnaReddy D.

Int Immunopharmacol. 2024 Nov 15;141:112940. doi: 10.1016/j.intimp.2024.112940. Epub 2024 Aug 17.

Tau proteins and senescent Cells: Targeting aging pathways in Alzheimer's disease

Singh M, Ali H, Renuka Jyothi S, Kaur I, Kumar S, Sharma N, Siva Prasad GV, Pramanik A, Hassan Almalki W, Imran M.

Brain Res. 2024 Dec 1;1844:149165. doi: 10.1016/j.brainres.2024.149165. Epub 2024 Aug 20.

Speech-related parameters are sensitive measures of acetylcholinesterase inhibitor therapy in mild Alzheimer's disease

Hegedűs É, Pákáski M, Gosztolya G, Hoffmann I, Kovács I, Kálmán J.

PLoS One. 2024 Aug 20;19(8):e0308409. doi: 10.1371/journal.pone.0308409. eCollection 2024.

Targeting STAT3 signaling pathway in the treatment of Alzheimer's disease with compounds from natural products

Wen X, Hu J.

Int Immunopharmacol. 2024 Nov 15;141:112936. doi: 10.1016/j.intimp.2024.112936. Epub 2024 Aug 19.

Recent Molecular Targets and their Ligands for the Treatment of Alzheimer Disease

Bayraktar G, Alptüzün V.

Curr Top Med Chem. 2024;24(28):2447-2464. doi: 10.2174/0115680266318722240809050235.

Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges

Tran J, Parekh S, Rockcole J, Wilson D, Parmar MS.

Life Sci. 2024 Oct 15;355:123001. doi: 10.1016/j.lfs.2024.123001. Epub 2024 Aug 21.

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies

Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L.

Signal Transduct Target Ther. 2024 Aug 23;9(1):211. doi: 10.1038/s41392-024-01911-3.

Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer's disease

Zhang Y, Yu W, Zhang L, Li P.

Expert Opin Investig Drugs. 2024 Oct;33(10):1047-1062. doi: 10.1080/13543784.2024.2396911. Epub 2024 Aug 26.

Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)

Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS.

J Alzheimers Dis. 2024;101(1):353-367. doi: 10.3233/JAD-240221.

Approved drugs and natural products at clinical stages for treating Alzheimer's disease

Ma Y, Liu S, Zhou Q, Li Z, Zhang Z, Yu B.

Chin J Nat Med. 2024 Aug;22(8):699-710. doi: 10.1016/S1875-5364(24)60606-0.

Interconnections between the Gut Microbiome and Alzheimer's Disease: Mechanisms and Therapeutic Potential

Sait AM, Day PJR.

Int J Mol Sci. 2024 Aug 7;25(16):8619. doi: 10.3390/ijms25168619.

A Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease across a Decade of Research

Tyrakis P, Agridi C, Kourti M.

Int J Mol Sci. 2024 Aug 7;25(16):8630. doi: 10.3390/ijms25168630.

Estrogen Receptors: A New Frontier in Alzheimer's Disease Therapy

Cipriano GL, Mazzon E, Anchesi I.

Int J Mol Sci. 2024 Aug 21;25(16):9077. doi: 10.3390/ijms25169077.

Transient receptor potential channels as an emerging target for the treatment of Alzheimer's disease: Unravelling the potential of pharmacological interventions

Joshi N, Vaidya B, Sharma SS.

Basic Clin Pharmacol Toxicol. 2024 Oct;135(4):375-400. doi: 10.1111/bcpt.14073. Epub 2024 Aug 29.

Efficacy of selective serotonin reuptake inhibitors-related antidepressants in Alzheimer's disease: a meta-analysis

Wang H, Li S, Zhang J, Peng W, Li T, Zhang J.

Eur J Med Res. 2024 Aug 29;29(1):438. doi: 10.1186/s40001-024-02006-z.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias